THE US FDA has approved
Levemir (insulin detemir [rDNA
origin] injection) for use in children
aged 2-5 years with type 1 diabetes.
The FDA approval now makes
Levemir the first and only basal
insulin analog in the US for use in
this young patient group.
The above snippet is the first part of an article sent to subscribers in Pharmacy Daily's issue from 23 May 12
Established in 2007, Pharmacy Daily is Australia's leading pharmacy industry publication, and is sent as a free subscription to people across the industry as a PDF newsletter every weekday.
To sign up for a free subscription, click on the button at right.
